Based on the provided paper content, I will answer each question systematically.

"""
Question: 1101

Evidence: All data relevant to this study were included in the main text and supplementary information. We have adapted a low-cost, easy-to-use, rapid OLA- Simple HIVDR test for a Mexican population.

Rationale: The paper describes a validation study of the OLA-Simple test in a Mexican cohort, presenting new clinical validation results, probe adaptations, and software analysis. The "Data availability statement" confirms that all relevant data are included, indicating this is a report of the study's own findings.

Answer: Yes
"""

"""
Question: 1102

Evidence: A database containing HIVDR profiles from 2412 individuals initiating first-line ART in Mexico City genotyped by MiSeq was used to select 60 plasma specimens. De-identified specimens from treatment-naive adults were blindly tested by OLA-Simple , and the results compared to results from MiSeq sequencing.

Rationale: The paper explicitly states that HIV sequences were generated through MiSeq sequencing of plasma specimens from individuals in Mexico City, and these sequences were used for HIV drug resistance profiling and comparison with OLA-Simple results.

Answer: Yes
"""

"""
Question: 1103

Evidence: No evidence found in the paper content about in vitro passage experiments.

Rationale: After thoroughly reviewing the paper content, I found no mention of in vitro passage experiments. The study focuses on clinical validation of the OLA-Simple test using patient plasma specimens, not laboratory passage experiments.

Answer: No
"""

"""
Question: 1104

Evidence: No evidence found in the paper content about in vitro antiretroviral susceptibility data.

Rationale: The paper describes genotypic resistance testing using OLA-Simple and MiSeq sequencing, but does not report any phenotypic susceptibility testing or IC50 values for antiretroviral drugs.

Answer: No
"""

"""
Question: 2101

Evidence: GenBank accession numbers are MT044195-MT044237; MT070765-MT070781.

Rationale: The methods section explicitly states the GenBank accession numbers for the sequenced HIV isolates from this study.

Answer: Yes
"""

"""
Question: 2102

Evidence: GenBank accession numbers are MT044195-MT044237; MT070765-MT070781. De-identified specimens from treatment-naive adults were blindly tested by OLA-Simple , and the results compared to results from MiSeq sequencing.

Rationale: The GenBank accession numbers provided are for sequences obtained from clinical specimens of treatment-naive adults in Mexico City, not laboratory HIV isolates.

Answer: Yes
"""

"""
Question: 2103

Evidence: GenBank accession numbers are MT044195-MT044237; MT070765-MT070781.

Rationale: The methods section clearly lists the specific GenBank accession numbers for the sequences generated in this study.

Answer: MT044195-MT044237; MT070765-MT070781
"""

"""
Question: 2202

Evidence: Deep sequencing by MiSeq (Illumina, San Diego, California, USA) on near-full genome HIV amplicons was performed. Amino acid mutations were queried against the Stanford HIV Drug Resistance Database.

Rationale: The paper describes using MiSeq deep sequencing to detect HIV drug resistance mutations and querying them against the Stanford database, indicating that mutation lists for individual sequenced isolates were generated and analyzed.

Answer: Yes
"""

"""
Question: 2301

Evidence: In this study, we have further improved the OLA- Simple assay. We have adapted the OLA-Simple kit probe sequences to detect these NNRTI/NRTI mutations in a Mexican population.

Rationale: The paper focuses on HIV-1, as it mentions adapting OLA-Simple for HIV-1 and testing in a Mexican population where HIV-1 is prevalent. No other HIV species are mentioned.

Answer: HIV-1
"""

"""
Question: 2302

Evidence: To improve ligation efficiency in the Mexican cohort, where HIV subtype B accounts for nearly 99% of infections. OLA-Simple probes designed to detect K65R, K103N/S, Y181C, M184V, and G190A across multiple subtypes were modified to include polymorphisms observed frequently in pol sequences from individuals initiating an NNRTI/NRTI regimen in Mexico City.

Rationale: The discussion section explicitly states that HIV subtype B accounts for nearly 99% of infections in the Mexican cohort studied, and probes were adapted for this subtype.

Answer: Subtype B
"""

"""
Question: 2303

Evidence: Deep sequencing by MiSeq (Illumina, San Diego, California, USA) on near-full genome HIV amplicons was performed. The alignment of 2412 Mexican HIV pol sequences showed considerable variability in the area of several OLA-Simple kit probes.

Rationale: The paper mentions sequencing "near-full genome HIV amplicons" and specifically references analysis of pol sequences, indicating that the pol gene was sequenced.

Answer: pol gene
"""

"""
Question: 2304

Evidence: Deep sequencing by MiSeq (Illumina, San Diego, California, USA) on near-full genome HIV amplicons was performed. The alignment of 2412 Mexican HIV pol sequences showed considerable variability.

Rationale: The paper explicitly states that HIV pol sequences were generated and analyzed from the Mexican cohort, both for the larger database of 2412 individuals and the 60 specimens selected for OLA-Simple validation.

Answer: Yes
"""

"""
Question: 2401

Evidence: Validated the improved kits by genotyping PDR in a cohort of adults initiating first-line NNRTI/NRTI regimens in Mexico City. A database containing HIVDR profiles from 2412 individuals initiating first-line ART in Mexico City genotyped by MiSeq was used to select 60 plasma specimens.

Rationale: The paper clearly states that the study was conducted on specimens from Mexico City, Mexico.

Answer: Mexico City, Mexico
"""

"""
Question: 2402

Evidence: OLA-Simple probes designed to detect K65R, K103N/S, Y181C, M184V, and G190A across multiple subtypes were modified to include polymorphisms observed frequently in pol sequences from individuals initiating an NNRTI/NRTI regimen in Mexico City between September 2017 and March 2018.

Rationale: The methods section specifies that probe modifications were based on sequences from individuals initiating treatment between September 2017 and March 2018, indicating when the samples were obtained.

Answer: September 2017 to March 2018
"""

"""
Question: 2502

Evidence: At present, in resource-limited settings (RLS), HIVDR testing using Sanger sequencing is limited to centralized laboratories. The analytical sensitivity of OLA-Simple is 10% mutant among the HIV quasi- species, which is better than the reported sensitivities of 20 â€“ 50% by Sanger sequencing.

Rationale: While the paper discusses Sanger sequencing as a comparison method, it explicitly states that the current study used MiSeq (an NGS technology) for sequencing, not Sanger sequencing.

Answer: No
"""

"""
Question: 2503

Evidence: A database containing HIVDR profiles from 2412 individuals initiating first-line ART in Mexico City genotyped by MiSeq was used to select 60 plasma specimens. Deep sequencing by MiSeq (Illumina, San Diego, California, USA) on near-full genome HIV amplicons was performed.

Rationale: The paper explicitly states that MiSeq (Illumina MiSeq) was used for sequencing, which is a next-generation sequencing (NGS) technology.

Answer: Yes
"""

"""
Question: 2504

Evidence: No evidence found in the paper content about cloning prior to sequencing.

Rationale: The paper describes direct sequencing of plasma specimens using MiSeq without mentioning any cloning procedures prior to sequencing.

Answer: No
"""

"""
Question: 2505

Evidence: No evidence found in the paper content about single genome sequencing.

Rationale: The paper describes using MiSeq deep sequencing but does not mention single genome sequencing specifically.

Answer: No
"""

"""
Question: 2506

Evidence: No evidence found in the paper content about molecular cloning.

Rationale: The methods describe direct sequencing of plasma specimens using MiSeq without mentioning molecular cloning procedures.

Answer: No
"""

"""
Question: 2601

Evidence: De-identified specimens from treatment-naive adults were blindly tested by OLA-Simple , and the results compared to results from MiSeq sequencing. Plasma specimens were extracted using the Qiagen QIAamp Viral RNA kit.

Rationale: The paper explicitly states that plasma specimens were used for sequencing and testing, indicating plasma HIV sequencing was performed.

Answer: Yes
"""

"""
Question: 2602

Evidence: No evidence found in the paper content about PBMC HIV sequencing.

Rationale: The paper only mentions plasma specimen testing and does not reference PBMC sequencing or proviral DNA analysis.

Answer: No
"""

"""
Question: 2603

Evidence: A database containing HIVDR profiles from 2412 individuals initiating first-line ART in Mexico City genotyped by MiSeq was used to select 60 plasma specimens. Clinical validation of this version of the OLA-Simple was conducted on 60 plasma specimens from a cohort in Mexico.

Rationale: The paper states that 60 plasma specimens were selected from a larger database of 2412 individuals and underwent plasma virus sequencing and OLA-Simple testing.

Answer: 60
"""

"""
Question: 2604

Evidence: No evidence found in the paper content about PBMC virus sequencing.

Rationale: The paper only describes plasma specimen testing and does not mention PBMC virus sequencing.

Answer: 0
"""

"""
Question: 2605

Evidence: De-identified specimens from treatment-naive adults were blindly tested. Across these specimens, 98.3% (59/60) amplified by reverse transcription polymerase chain reaction (RT-PCR) (median viral load: 103 586, range 176--10 000 000 copies/ml).

Rationale: The paper describes testing plasma specimens from treatment-naive individuals with detectable viral loads, indicating active HIV replication was present.

Answer: Yes
"""

"""
Question: 2606

Evidence: No evidence found in the paper content about sequences obtained from proviral DNA reservoir.

Rationale: The paper specifically mentions plasma specimen testing and RNA extraction, indicating sequencing was performed on viral RNA from plasma, not proviral DNA from cells.

Answer: No
"""

"""
Question: 2701

Evidence: In women and children with previous exposure to antiretroviral drugs for prevention of mother-to-child transmission (MTCT) of HIV, PDR to nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) can be up to 30 and 75%, respectively.

Rationale: While the introduction mentions children in the context of general HIVDR prevalence, the methods section specifies that the study used "specimens from treatment-naive adults," indicating no infants or children were included in the actual study cohort.

Answer: No
"""

"""
Question: 2702

Evidence: No evidence found in the paper content about individuals in a clinical trial.

Rationale: The paper describes a validation study of the OLA-Simple test using clinical specimens, but does not mention that individuals were participating in a clinical trial.

Answer: No
"""

"""
Question: 2703

Evidence: No evidence found in the paper content about individuals in a clinical trial.

Rationale: The paper does not mention clinical trial participation for any individuals in the study.

Answer: No
"""

"""
Question: 3101

Evidence: A database containing HIVDR profiles from 2412 individuals initiating first-line ART in Mexico City genotyped by MiSeq was used to select 60 plasma specimens.

Rationale: The paper states that a database of 2412 individuals was used to select 60 specimens for the study, indicating that HIV sequencing was performed on samples from 2412 individuals.

Answer: 2412
"""

"""
Question: 3102

Evidence: A database containing HIVDR profiles from 2412 individuals initiating first-line ART in Mexico City genotyped by MiSeq was used to select 60 plasma specimens.

Rationale: The paper indicates that all 2412 individuals in the database had HIV sequencing performed by MiSeq, from which 60 were selected for OLA-Simple validation.

Answer: Yes
"""

"""
Question: 4101

Evidence: De-identified specimens from treatment-naive adults were blindly tested by OLA-Simple , and the results compared to results from MiSeq sequencing.

Rationale: The methods section explicitly states that specimens were from "treatment-naive adults," indicating ART-naive individuals.

Answer: Yes
"""

"""
Question: 4102

Evidence: No evidence found in the paper content about individuals who had previously received ARV drugs.

Rationale: The paper specifically states that specimens were from "treatment-naive adults," indicating no ART-experienced individuals were included in the study cohort.

Answer: No
"""

"""
Question: 4103

Evidence: De-identified specimens from treatment-naive adults were blindly tested by OLA-Simple.

Rationale: The paper explicitly states that all specimens were from treatment-naive adults, with no mention of ART-experienced individuals.

Answer: No
"""

"""
Question: 4104

Evidence: De-identified specimens from treatment-naive adults were blindly tested by OLA-Simple. Clinical validation of this version of the OLA-Simple was conducted on 60 plasma specimens from a cohort in Mexico.

Rationale: The paper states that all 60 plasma specimens used in the study were from treatment-naive adults.

Answer: 60
"""

"""
Question: 4105

Evidence: De-identified specimens from treatment-naive adults were blindly tested by OLA-Simple.

Rationale: The paper confirms that all individuals were treatment-naive, providing complete ART history information for the study cohort.

Answer: Yes
"""

"""
Question: 4201

Evidence: Validated the improved kits by genotyping PDR in a cohort of adults initiating first-line NNRTI/NRTI regimens in Mexico City. We have adapted a low-cost, easy-to-use, rapid OLA- Simple HIVDR test for a Mexican population.

Rationale: The paper describes genotyping pretreatment drug resistance (PDR) in a cohort of adults initiating first-line ART, which is equivalent to transmitted HIV drug resistance in treatment-naive individuals.

Answer: Yes
"""

"""
Question: 4202

Evidence: Validated the improved kits by genotyping PDR in a cohort of adults initiating first-line NNRTI/NRTI regimens in Mexico City.

Rationale: The paper explicitly states that the study involved genotyping pretreatment HIV drug resistance (PDR) in the Mexican cohort.

Answer: Yes
"""

"""
Question: 4301

Evidence: This set of mutations was selected due to their frequency in the Mexican cohort and their relevance for the preferred first-line regimens in use at the time of study design. Specifically, we have designed probes to detect major drug resistance mutations to NNRTIs (EFV/NVP) and NRTIs (3TC/TDF).

Rationale: The paper mentions that the mutations tested are relevant to NNRTI and NRTI drug classes, and that individuals were initiating first-line NNRTI/NRTI regimens.

Answer: NNRTIs, NRTIs
"""

"""
Question: 4302

Evidence: No evidence found in the paper content about individuals who received integrase inhibitors.

Rationale: The paper describes testing treatment-naive individuals initiating first-line NNRTI/NRTI regimens, with no mention of integrase inhibitor use in the study cohort.

Answer: No
"""

"""
Question: 4303

Evidence: No evidence found in the paper content about individuals who received protease inhibitors.

Rationale: The paper describes testing treatment-naive individuals initiating first-line NNRTI/NRTI regimens, with no mention of protease inhibitor use in the study cohort.

Answer: No
"""

"""
Question: 4304

Evidence: Validated the improved kits by genotyping PDR in a cohort of adults initiating first-line NNRTI/NRTI regimens in Mexico City.

Rationale: The paper states that all individuals were initiating first-line NNRTI/NRTI regimens, indicating they all received the same ART class combination.

Answer: Yes
"""

"""
Question: 4305

Evidence: Validated the improved kits by genotyping PDR in a cohort of adults initiating first-line NNRTI/NRTI regimens in Mexico City.

Rationale: Since all individuals were treatment-naive and initiating first-line NNRTI/NRTI regimens, they would be INSTI-naive (integrase strand transfer inhibitor naive).

Answer: Yes
"""

"""
Question: 4403

Evidence: De-identified specimens from treatment-naive adults were blindly tested by OLA-Simple.

Rationale: All individuals were treatment-naive, meaning they had not received any prior ART regimens and were just starting their first regimen.

Answer: 0
"""

"""
Question: 4404

Evidence: De-identified specimens from treatment-naive adults were blindly tested by OLA-Simple.

Rationale: All individuals were treatment-naive, meaning they had not received any prior ART regimens.

Answer: 0
"""

"""
Question: 4405

Evidence: De-identified specimens from treatment-naive adults were blindly tested by OLA-Simple.

Rationale: Since all individuals were treatment-naive, they all received the same number of ART regimens (zero prior regimens).

Answer: Yes
"""

"""
Question: 4406

Evidence: De-identified specimens from treatment-naive adults were blindly tested by OLA-Simple.

Rationale: The paper states that specimens were from treatment-naive adults, meaning they had not received any ART regimens prior to the study.

Answer: Yes
"""

"""
Question: 4501

Evidence: No evidence found in the paper content about individuals receiving dolutegravir.

Rationale: The paper describes testing treatment-naive individuals initiating first-line NNRTI/NRTI regimens, with no mention of dolutegravir use in the study cohort.

Answer: 0
"""

"""
Question: 4502

Evidence: No evidence found in the paper content about individuals receiving darunavir.

Rationale: The paper describes testing treatment-naive individuals initiating first-line NNRTI/NRTI regimens, with no mention of darunavir or protease inhibitor use in the study cohort.

Answer: 0
"""

"""
Question: 5101

Evidence: Clinical validation of this version of the OLA-Simple was conducted on 60 plasma specimens from a cohort in Mexico selected by collaborators at CIENI/INER to include a high proportion of specimens with PDR.

Rationale: The paper states that specimens were selected to include a high proportion with pretreatment drug resistance (PDR), but does not provide the exact number of individuals with one or more drug resistance mutation.

Answer: NA
"""

"""
Question: 5102

Evidence: No evidence found in the paper content about INSTI-resistance mutations.

Rationale: The paper focuses on NNRTI and NRTI resistance mutations (K65R, K103N/S, Y181C, M184V, G190A) and does not report any INSTI-resistance mutations.

Answer: 0
"""

"""
Question: 5103

Evidence: Table 1 shows genotyping results by OLA-Simple. For K65R (a TDF-resistance mutation), there was 1 true positive (MUT) result.

Rationale: Table 1 shows that for K65R (a major tenofovir resistance mutation), there was 1 true positive mutant result detected by OLA-Simple.

Answer: 1
"""

"""
Question:"""
Question: 5104

Evidence: No evidence found in the paper content about INSTI-resistance mutations.

Rationale: The paper focuses on NNRTI and NRTI resistance mutations (K65R, K103N/S, Y181C, M184V, G190A) and does not report any specific INSTI-resistance mutations developing in individuals.

Answer: NA
"""

"""
Question: 6101

Evidence: No evidence found in the paper content about phenotypic susceptibility testing.

Rationale: The paper describes genotypic resistance testing using OLA-Simple and MiSeq sequencing, but does not mention any phenotypic susceptibility testing methods.

Answer: NA
"""

"""
Question: 6102

Evidence: No evidence found in the paper content about IC values like IC50 or IC90.

Rationale: The paper focuses on genotypic resistance testing and does not report any IC50, IC90, or other inhibitory concentration values.

Answer: No
"""

"""
Question: 6103

Evidence: No evidence found in the paper content about IC50 fold change values.

Rationale: The paper describes genotypic resistance testing methods but does not mention IC50 fold change values or phenotypic susceptibility testing.

Answer: No
"""

"""
Question: 6104

Evidence: No evidence found in the paper content about phenotypic susceptibility assays.

Rationale: The paper focuses on genotypic resistance testing using OLA-Simple and MiSeq sequencing, with no mention of phenotypic susceptibility assays.

Answer: NA
"""

"""
Question: 6105

Evidence: No evidence found in the paper content about replication capacity data.

Rationale: The paper does not mention replication capacity testing or data for any HIV isolates.

Answer: No
"""

"""
Question: 6106

Evidence: No evidence found in the paper content about drugs tested in phenotypic susceptibility assays.

Rationale: The paper describes genotypic testing for mutations associated with NNRTIs (EFV/NVP) and NRTIs (3TC/TDF), but does not report any phenotypic susceptibility testing of specific drugs.

Answer: NA
"""

"""
Question: 7101

Evidence: Assay optimization was performed using HIV subtype B plasmids mixtures containing 0, 10, 25, and 100% mutant for all codons tested as previously described.

Rationale: The paper mentions using plasmid DNA standards for assay optimization, but these are described as mixtures of wild-type and mutant plasmids for analytical sensitivity testing, not site-directed mutants created for the study.

Answer: No
"""

"""
Question: 7102

Evidence: No evidence found in the paper content about in vitro passage experiments.

Rationale: The paper describes a clinical validation study using patient plasma specimens and does not mention any in vitro passage experiments to generate isolates.

Answer: No
"""